Singapura - Inggeris - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 75mg

Malaysia - Inggeris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - dupilumab -

Arab Saudi - Inggeris - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis france, france - valproate sodium - powder and solvent for solution for injection - 100 mg/ml

Mesir - Inggeris - EDA (Egyptian Drug Authority)

sanofi-synthelabo france - enteric coated tablet - 200 mg

Mesir - Inggeris - EDA (Egyptian Drug Authority)

sanofi-synthelabo france - syrup - 5.764 gm/100ml

Singapura - Inggeris - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - vigabatrin - tablet, film coated - 500 mg - vigabatrin 500 mg

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - hepatitis a virus antigen, quantity: 320 agu/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; hydrochloric acid; neomycin; phenoxyethanol; formaldehyde; sodium hydroxide; polysorbate 80; ethanol absolute; glucose monohydrate; ascorbic acid; sodium chloride; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; monobasic potassium phosphate; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic - avaxim is indicated for: active immunisation against hepatitis a infections in adults and children 2 years and older who are or will be at increased risk of infection: - travellers to areas of moderate or high endemicity for hepatitis a. - visitors to rural and remote indigenous communities. - child day-care and pre-school personnel. - the intellectually disabled and their carers. -health care providers. - sewerage workers. - men who have sex with men. - injecting drug users. - patients with chronic liver disease. - haemophiliacs who may receive pooled plasma concentrates.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - bromhexine hydrochloride, quantity: 0.8 mg/ml - oral liquid - excipient ingredients: benzoic acid; maltitol solution; menthol; purified water; sucralose; flavour - for use as a mucolytic to break down mucus and help clear the chest in conditions accompanied by excessive mucus secretions, such as in the common cold, influenza, infections of the respiratory tract or in other conditions where excess mucus is produced.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - hepatitis a virus antigen, quantity: 320 agu/ml - injection, suspension - excipient ingredients: neomycin; polysorbate 80; formaldehyde; aluminium hydroxide hydrate; phenoxyethanol; hydrochloric acid; sodium hydroxide; ethanol absolute; glucose monohydrate; ascorbic acid; sodium chloride; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; monobasic potassium phosphate; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic acid; inositol; menadione; nicotinic acid; nicotinamide; aminobenzoic acid; pyridoxal hydrochloride; pyridoxine hydrochloride; riboflavine; thiamine hydrochloride; retinol acetate; dl-alpha-tocopheryl phosphate disodium - avaxim is indicated for: active immunisation against hepatitis a infections in adults and children 2 years and older who are or will be at increased risk of infection: - travellers to areas of moderate or high endemicity for hepatitis a. - visitors to rural and remote indigenous communities. - child day-care and pre-school personnel. - the intellectually disabled and their carers. -health care providers. - sewerage workers. - men who have sex with men. - injecting drug users. - patients with chronic liver disease. - haemophiliacs who may receive pooled plasma concentrates.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - bromhexine hydrochloride, quantity: 0.8 mg/ml - oral liquid - excipient ingredients: maltitol solution; hyetellose; benzoic acid; sucralose; purified water; flavour - for use as a mucolytic to break down mucus and help clear the chest in conditions accompanied by excessive mucus secretions, such as in the common cold, influenza, infections of the respiratory tract or in other conditions where excess mucus is produced.